Log In
Sunday 24th September 2017

Asthma guidance welcomed

5th December 2007

Drug manufacturer GlaxoSmithKline has welcomed guidance issued by the National Institute of Health and Clinical Excellence (NICE) on chronic asthmas in children under 12 years old.

The guidance recommends combination treatments such as Seretide®* (salmeterol/fluticasone propionate) as an option for children, needing both an inhaled corticosteroid (ICS) and a long-acting beta2 agonist (LABA) to control their asthma. The guidance gives healthcare professionals the freedom to choose between a combination treatment or separate devices for ICS. About one million children in the UK are known to have asthma.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2017